Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The 2025 respiratory research days: A first in Caen!]

Revue des maladies respiratoires·2026
Same author

Assessing air pollution exposure in children at school: toward a source-specific exposure matrix.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

[On your marks, get set, go for the 20th edition of J2R 2024 in Paris!]

Revue des maladies respiratoires·2025
Same author

Asthma and allergies in schoolchildren: data from the European SINPHONIE study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Use of a mobile sensor to measure PM<sub>2.5</sub> and its fluctuations with weather conditions in Bangkok.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Low-cost air quality portable sensors and their potential use in respiratory health.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

The decrease in asthma-related mortality in France.

S Tual1, P Godard, J Bousquet

  • 1Epidémiologie des maladies allergiques et respiratoires (EPAR), UMR S 707 Inserm, 75012 Paris, France.

Revue Des Maladies Respiratoires
|September 25, 2010
PubMed
Summary
This summary is machine-generated.

Asthma mortality in France significantly decreased between 1980-2005, particularly for adults over 35. This trend suggests improved patient care and death recording practices are positively impacting public health outcomes.

More Related Videos

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
15:00

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jun 8, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
15:00

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies

Published on: February 3, 2023

Area of Science:

  • Public Health
  • Epidemiology
  • Respiratory Medicine

Background:

  • Asthma poses a significant public health challenge, evidenced by substantial morbidity, mortality, and socioeconomic costs.
  • Despite available therapies, asthma caused approximately 2000 deaths in France in 1999, highlighting an ongoing public health concern.

Purpose of the Study:

  • To analyze trends in asthma-related mortality in metropolitan France from 1980 to 2005.
  • To investigate regional variations in asthma mortality rates across France.

Main Methods:

  • Calculated annual age- and gender-specific mortality rates for asthma.
  • Employed log-linear regression to estimate the annual average rate of change in mortality.
  • Utilized mapping techniques to visualize regional disparities in asthma mortality.

Main Results:

  • Asthma mortality rates stabilized between 1990-1995 before showing a significant decline.
  • The decrease in mortality was more pronounced in men than in women from 2000 onwards.
  • Significant reductions in asthma mortality were observed primarily in individuals aged over 35, with 1129 deaths recorded in 2005. Regional disparities were also evident.

Conclusions:

  • The downward trend in asthma mortality, initiated in 1986, persisted through 2005.
  • Potential contributing factors include enhanced patient management strategies, such as the increased use of inhaled corticosteroids and therapeutic education.
  • Improvements in the accuracy of death recording may also have influenced the observed mortality trends.